Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | HTR1B | P28222 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1619391 | 0.85 | KCNH2 (0.48) | KDM4EALDH1A1KDM1AHTTHRH3 | |
| SCHEMBL4133463 | 0.81 | KCNH2 (0.54) | KDM4EALDH1A1HTTL3MBTL1HRH3 | |
| SCHEMBL4134395 | 0.80 | KCNH2 (0.49) | KDM4EALDH1A1KDM1AHRH3 | |
| SCHEMBL1620192 | 0.80 | KDM4E (0.51) | KDM4EALDH1A1MEN1KMT2ATDP1 | |
| SCHEMBL4130153 | 0.77 | KCNH2 (0.51) | KDM4EALDH1A1HRH3 | |
| SCHEMBL4133154 | 0.76 | KCNH2 (0.43) | KDM4EALDH1A1HTT | |
| SCHEMBL4128894 | 0.76 | KCNH2 (0.46) | KDM4EALDH1A1MEN1KMT2ATDP1 | |
| SCHEMBL6150612 | 0.74 | KDM4E (0.43) | KDM4EALDH1A1MEN1KMT2ATDP1 | |
| Azd1305 SCHEMBL3120188 | 0.73 | KCNH2 (0.46) | KDM4EALDH1A1HRH3 | |
| SCHEMBL4139906 | 0.73 | KCNH2 (0.56) | KDM4EALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054422-A1 | New Oxabispidine Compounds For The Treatment Of Cardiac Arrhythmias | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | claimed |
| US-20090054422-A1 | New Oxabispidine Compounds For The Treatment Of Cardiac Arrhythmias | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054422-A1 | New Oxabispidine Compounds For The Treatment Of Cardiac Arrhythmias | RYR1, KCNH1, CACNA1E | KDM4E 3729/4885ALDH1A1 1142/4885MEN1 1955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.